EVE16 Engineering
The Right Engineering
EVE16 (Enhanced Valence Engineered CD16A) is the core of our cell therapy engineering technology. This proprietary non-CAR engineering enhances the Memory Like phenotype of PuNK Cells, adding potent tumor specific killing whilst minimising cellular exhaustion, trogocytosis or fratricide.
Click below to see a short animation
The basic premise of EVE16 is simple yet elegant. CD16A is the most potent activating receptor on Natural Killer Cells and is responsible for Antibody Dependent Cellular Cytotoxicity (ADCC). By engineering in an additional target receptor on the CD16A molecule, we are able to add antigen-specific tumor cell killing, whilst enhancing the innate killing activity.
Like CD16A, EVE16 is cleaved by ADAM17 upon cellular activation, thus releasing the activating signal and returning the cell to its base state. The key advantages are thus:
Added Anitgen-Dependent
NK Cell Killing
Pre-clinical data show that EVE16 armed NK cells out-perform conventional CAR armed NK cells in target antigen-high cell killing assays
Added Antigen-Independent
NK Cell Killing
Pre-clinical data show that EVE16 armed NK cells out-perform conventional CAR armed NK cells in target antigen-low cell killing assays.
Reduced Tonic Signalling
EVE16 cleavage by ADAM17 reduces tonic signalling and thus minimises cellular exhaustion and enhances repeat killing.
Reduced Trogocytosis
Reduced trogocytosis leads to enhanced NK Cell repeat killing and persistence.
